Inflammation is a key component of the initiation and progression of diseases such as DMD, thus, activating the integrated signalling network involving Nrf2, NF-κB and HO-1 is a logical approach in DMD treatment. The gene discussed is NFKB1; the disease is Duchenne muscular dystrophy.